Form 8-K TETRAPHASE PHARMACEUTICA For: Feb 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at Stifel; Path Forward Complicated, But Still There
February 14, 2018 6:28 AM ESTStifel lowered its price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $6.00 (from $13.00) while maintaining a Buy rating following the Phase 3 IGNITE3 trial failure.
Analyst Stephen Willey commented, "The failure of the P3 IGNITE3 trial to demonstrate the non-inferiority (NI) of intravenously-administered eravacycline vs.... More
